Neoadjuvant therapy for hepatocellular carcinoma:recent advances
10.16781/j.CN31-2187/R.20240060
- VernacularTitle:肝细胞癌新辅助治疗研究新进展
- Author:
Zonghan LIU
1
;
Liheng LIU
;
Kang WANG
;
Yuqiang CHENG
;
Shuqun CHENG
Author Information
1. 海军军医大学(第二军医大学)第三附属医院肝外六科,上海 200438
- Keywords:
hepatocellular carcinoma;
neoadjuvant therapy;
local therapy;
systemic therapy;
combination therapy
- From:
Academic Journal of Naval Medical University
2025;46(9):1189-1194
- CountryChina
- Language:Chinese
-
Abstract:
Hepatocellular carcinoma(HCC)is the fourth leading cause of cancer death in the world,and its prognosis is poor.Most HCC patients are diagnosed at an advance stage and are not candidates for surgery.Even if the early-stage tumor is resected,HCC patients tend to relapse within 5 years.In the era of targeted therapy and immunotherapy,neoadjuvant therapy has gained increasing attention and recommendation.For HCC patients with high recurrence risk,neoadjuvant therapy refers to preoperative local or systemic therapy,which can reduce tumor burden,remove tiny lesions,widen surgical margin,and reduce the recurrence risk.However,if the neoadjuvant therapy is not optimal,the timing of surgery will be delayed,resulting in disease progression or even loss of the chance for surgery.This article reviews the research progress of neoadjuvant therapy for HCC.
